AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $10.639 million which beat the analyst consensus estimate of $8.416 million by 26.41 percent. This is a 18.81 percent increase over sales of $8.955 million the same period last year.